NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product ...

The agreement with NanoVation marks the second big recent deal that a B.C. biotech startup has struck with the Danish ...

Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE:NVO) to advance the ...

NanoVation Therapeutics, a Vancouver company co-founded by biotech magnate Pieter Cullis, has struck a partnership with ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...

Canada’s NanoVation Therapeutics has partnered with Novo Nordisk to advance genetic medicines for cardiometabolic and rare ...

The firms will collaborate on two lead programs and up to five future targets in other diseases, with NanoVation eligible for up to $600 million in payments from Novo Nordisk.

RA Capital Management, LP ("RA Capital"), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today ...

The Federal Reserve yesterday cut interest rates by 50 basis points, in its first time cutting rates in four years. And how ...

Eli Lilly and Novo Nordisk currently lead this market, but smaller competitors such as Roche, Pfizer, Amgen, and Viking are ramping up their efforts in developing weight-loss treatments.

(RTTNews) - Biopharmaceutical company Korro Bio, Inc. (KRRO) announced Monday a collaboration with Danish healthcare company Novo Nordisk A/S (NVO) to advance the discovery and development of new ...

Bagsværd, Denmark, 16 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and ...